Understand first,
then ask better questions.

Regenerative medicine is a broad field concerned with supporting, repairing or replacing cells, tissues or biological functions. It includes different technologies and products; it is not another name for one single treatment.

No. MSCs are multipotent cells; NK cells are immune cells; exosomes are cell-released extracellular vesicles; NAD+ is a cellular coenzyme; and peptides are short chains of amino acids. Their preparation, evidence, regulation and clinical roles differ.

Autologous means the starting cells or tissue come from the same person who will receive the resulting product. Allogeneic means they come from another eligible donor.

Health history, current conditions, medicines, examination findings, investigations and standard-care options may affect risk and suitability. The required assessment depends on the proposed procedure and the doctor’s judgement.

It should not be assumed to do so. A doctor should explain the clinical status, evidence, alternatives and whether standard care should continue.

You may prepare a concise symptom and treatment history, current medicines and recent investigations. Any required documents and submission method will be explained during coordination.

MSC commonly refers to Mesenchymal Stem Cells. Some scientific and regulatory documents use Mesenchymal Stromal Cells. They are multipotent cells studied for tissue support, signalling and repair-related processes.

The resource is allogeneic MSC derived from Wharton’s jelly, the connective tissue within donated umbilical cords collected after delivery.

Donation follows informed consent and donor eligibility procedures. Collection is undertaken through hospitals under the applicable ethical and health-authority-approved programme, with relevant records and traceability.

A recent health assessment and the medical information requested by the clinic are required. A licensed doctor reviews medical history, investigations, current conditions and potential risks before deciding whether the person may proceed.

A known, suspected or currently investigated malignancy requires medical review and may mean the procedure is deferred or not offered. The treating doctor determines what further investigation or specialist clearance is required; VANORÉ does not make this decision.

No. Cell source and laboratory quality do not determine individual suitability. A doctor must consider medical findings, evidence, alternatives and potential risks.

Natural Killer cells are part of the innate immune system and can recognise certain abnormal or infected cells. Cell source, processing, culture and clinical arrangements can differ substantially.

Both categories may be explored. VANORÉ primarily coordinates autologous NK-cell resources, where the person’s own blood is used as the starting sample.

After medical assessment, a blood sample is collected and sent to the laboratory. NK cells are isolated, activated and expanded ex vivo, followed by applicable quality testing and release. The client then returns according to the clinic’s schedule for the doctor-led clinical stage.

Cell isolation, activation, expansion and quality review require time. About 21 days is an indicative operational timeframe, not a guarantee; sample characteristics, culture performance, testing and release may affect the schedule.

Not necessarily. Travel and return timing depend on the blood-collection appointment, laboratory schedule, release status and clinic plan. Coordination should be confirmed before travel is booked.

Exosomes are small extracellular vesicles released by cells. They can carry proteins, lipids and nucleic acids involved in cell-to-cell communication. Products described as exosomes may differ in source, preparation and characterisation.

NAD+ is a naturally occurring coenzyme involved in cellular energy metabolism, redox reactions and other cell processes. A biological role does not by itself establish a particular clinical benefit.

Peptides are short chains of amino acids. Different peptides have different biological functions, evidence, legal status and medical uses, so each substance must be considered separately.

It refers here to doctor-led assessment and coordination for MSC or exosome-related intra-articular injection enquiries. It is not a single standardised treatment.

MSCs are cells, while exosomes are cell-released extracellular vesicles. Their composition, handling, evidence and clinical considerations differ. A doctor must explain which options, if any, are appropriate.

The clinic may request symptom history, previous treatments, examination findings and recent imaging such as X-rays or MRI. Requirements depend on the doctor and the knee condition.

No. Knee pain has many causes and degrees of severity. A doctor should first assess the diagnosis, structural findings, risks and standard-care alternatives.

Good Manufacturing Practice provides a system for consistent production and quality control across premises, equipment, personnel, procedures and records. It helps control risks that final-product testing alone may not address.

Good Tissue Practice covers donation, procurement, testing, processing, storage, distribution and traceability of cells and tissues. It is important for donor eligibility, contamination control, tissue integrity and traceability.

CGTP refers to Cell and Gene Therapy Products within Malaysia’s regulatory framework. The classification helps define applicable product, manufacturing, documentation and review requirements.

A Certificate of Analysis records tests, specifications and results for a defined batch. A batch-specific COA links quality and release information to the actual batch concerned.

GMP addresses manufacturing systems, GTP addresses tissue and cell practice, CGTP describes the regulatory product category, and a COA records batch analysis. Together they provide different parts of the quality picture.